![](https://s3.amazonaws.com/cache.altmetric.com/policy/thumbnails/thumbnail-11a159420dbadd125ed0603e1f6e550df1f8ed6f69a4a036705cc54a585c5043.jpg)
Lanreotide for the Treatment of Neuroendocrine Tumours: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines
Cited by Canadian Agency for Drugs and Technologies in Health on
CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.